Sandrine Piret-Gerard serves as SVP U.S. Commercial at Gilead Sciences with responsibility for the U.S. commercialization of all the company’s medicines throughout their lifecycle. Under her leadership, Gilead works to ensure that patients in the U.S. have access to the company’s transformational medicines in Virology (HIV, Liver diseases, COVID-19) and Oncology.

Sandrine joined Gilead in 2022 after 19 years at Novartis, where she held roles of increasing responsibilities at local, regional and global level, gaining broad experience in all aspects of the commercial business across geographies (Belgium, Switzerland, France, Germany and U.S.), therapeutic areas (esp. Cardiovascular, Neuroscience, Dermatology, and Oncology) and lifecycle stages (from shaping portfolio strategy with R&D, to launching, growing, defending and managing brands post LOE). Before joining Gilead Sandrine led the Solid Tumors and Hematology U.S. commercial organizations at Novartis. She then oversaw the Global Marketing, Value & Access as well as Portfolio Strategy for Novartis Oncology worldwide. Before joining Novartis, Sandrine worked at the Boston Consulting Group where she was a member of the Healthcare Practice Group.

Sandrine holds a bachelor’s degree in engineering from the Universite Catholique de Louvain, Belgium, and an MBA from INSEAD, France/Singapore.

She has been recognized among the “40 under 40 in business” in Germany in 2014, the “40 above 40 – World’s Most Inspiring Women” in 2022, and, in 2024, was recognized as a Luminary by the Healthcare Businesswomen’s Association (HBA). She is a member of the American Cancer Society Board of Ambassador since 2025.